MicroRNAs Modulating the Effect of Glucocorticoid Signaling
The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.
Glucocorticoid signalling plays a key role in diseases associated with metabolic syndrome, which are considered to become the major burden of human health in the 21th century. Thus, strategies for treating such diseases are urgently needed. The current invention describes an miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.
The invention has been successfully tested in an in vivo model of metabolic syndrome (db/db mouse).
Liver-specific knockdown of a specific miRNA which is involved in glucocorticoid receptor signalling can be used as a method for interfering with glucocorticoid-dependent pathologies, including diabesity-related dyslipidemia, hyperglycemia and insulin resistance. For example, it has been shown that liver-specific knockdown leads to a significant reduction of circulating VLDL-associated triglycerides in an in vivo mouse model of metabolic syndrome.
DKFZ is looking for a commercial partner to further develop this technology towards clinical application.